GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » 111 Inc (NAS:YI) » Definitions » Research & Development

111 (YI) Research & Development : $0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is 111 Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. 111's Research & Development for the three months ended in Dec. 2023 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.

111 Research & Development Historical Data

The historical data trend for 111's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

111 Research & Development Chart

111 Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial - - - - -

111 Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

111 Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

111  (NAS:YI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

111 Research & Development Related Terms

Thank you for viewing the detailed overview of 111's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

111 (YI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » 111 Inc (NAS:YI) » Definitions » Research & Development
Comparable Companies
PETS RXMD LFLY RADCQ MEDS MDVL BIMI HEWA CJJD SSY WBA BSP:RADL3 HKSE:00241 TSE:3088 SAU:4164 SHSE:603939 TSE:3349 SHSE:600998 HKSE:09885 TSE:3391
Traded in Other Exchanges
811A:Germany 811A:Germany
Address
No.295 ZuChongZhi Road, 3rd-5th Floors, Pudong New Area, Shanghai, CHN, 201203
Website
https://ir.111.com.cn
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.